Biolab sponsors José Ribeiro do Valle Award for young Brazilian scientists

Biolab Farmacêutica believes that investing in science is the answer to the continuous development of health in the country. In order to value the work of Brazilian researchers, we are supporting the Brazilian Society of Pharmacology and Experimental Therapeutics (SBFTE) for another year by sponsoring the José Ribeiro do Valle Award, which recognizes and rewards the work of young Brazilian scientists.

Dr. José Ribeiro do Valle, after whom the award is named, conceived and created the Institute of Pharmacology at UNIFESP (INFAR ? Institute of Pharmacology and Molecular Biology). He is being honored for his contribution to science and for being an inspiration to all those who know his story. The works entered for the award stand out for providing new knowledge, which makes their chances of success and their commercial potential feasible.

The winner of this edition was Nathália Ferreira de Oliveira, who has a degree in Pharmacy from the Federal University of Rio de Janeiro (UFRJ) and is studying for a PhD in Biological Sciences at the same institution.

For Dr. Dante Alario Jr., Pharmacist and CSO at Biolab, "one of the most important commitments presented at the event is the partnership between industries and educational entities, but the work must be done by everyone: researchers, industry and government must join forces to overcome obstacles and make the health of the population a priority. Joining forces increases the chances of research generating real benefits," he said.


"The SBFTE is an important organization for the work of expanding and valuing science, as it works to disseminate research, seeking partnerships and generating project opportunities. The scenario is challenging, but there is no shortage of researchers with a lot of potential. That's why we have a responsibility as an industry to encourage them," commented Dr. Danielle G. Passos Silva, Biolab's Technological Innovation Specialist.


Biolab invests in obtaining new technologies to benefit the population and works closely with various institutions. These initiatives lead to the development of new research, studies for specific purposes and the emergence of new medicines.


"The search for new health treatments is a frequent topic that has gained even more strength in the post-pandemic scenario. The challenges of innovation in Brazil are many and, in this context, it is essential to bring the industry closer to researchers in order to obtain new products. It should be emphasized that our job is always to meet the needs of patients in the safest and most effective way," says Marco Aurélio da Silva, Biolab's Vice President of Innovation and Quality.

PORTAL RBN/BA | 05/10/2023